>Core business momentum remains soft on overprovision reversals - Sales increased 22% y-o-y in Q3 2024 (vs -7% in Q2, +12% in Q1 and -20% in Q4). Biopharma sales decreased 5% y-o-y in Q3 2024 (compared to -18% in Q2, +25% in Q1 and -32% in Q4) namely owing to a reversal of overprovisions for deductions applicable under the French compassionate use programme, excluding this effect, 9M 2024 Lurbi sales in Europe are growing at a +14% pace (vs +16% in H1). Royalties post...
>Headline momentum appears weak but Lurbi keeps growing in underlying terms - Sales decreased 7% y-o-y in Q2 2024 (vs +12% in Q1 and -20% in Q4). Biopharma sales decreased 18% y-o-y in Q2 2024 (compared to +25% in Q1 and -32% in Q4) namely owing to a reversal of overprovisions for deductions applicable under the French compassionate use programme, excluding this effect H1 2024 Lurbi sales in Europe is growing at a +16% pace. Royalties posted a +18% y-o-y increase (vs ...
>Feedback from 52 companies present on day three - Our 13th edition of the ODDO BHF Nextcap Forum takes place on June 4 and 5 in Paris, and on June 6 virtually. Following the third day, which took place yesterday virtually at our Paris office with 52 companies in attendance, we publish hereafter feedback for those companies present:Aedas HomesLhyfeAfyrenMaisons Du MondeAltamirMcPhy EnergyAltriMister SpexAtresmediaNein...
>Feedback de 52 sociétés présentes le 3ème jour - Notre 13ème édition du ODDO BHF Nextcap Forum a lieu les 4 et 5 juin en physique à Paris et le 6 juin en virtuel. Suite à la troisième journée qui a eu lieu hier en virtuel avec 53 de sociétés présentes, nous publions ci-après un feedback pour chacune des sociétés couvertes :Aedas HomesLhyfeAfyrenMaisons Du MondeAltamirMcphy EnergyAltriMister SpexAtresmediaNeinor Homes§...
>Oncology gains momentum - Sales grew +12% y-o-y in Q1 2024 (vs -20% in Q4 and -9% in Q3). Biopharma sales increased +25% y-o-y in Q1 2024 (compared to -32% in Q4 and -27% in Q3) namely owing to higher revenues from Zepzelca and, to a lesser extent, also higher raw material and ‘early access’ sales. Royalties posted a +14% y-o-y increase (vs -6% in Q4 and+20% in Q3) while the more erratic licence revenues declined -8% which nonetheless implies a material sequential im...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.